Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily

被引:29
作者
Autar, RS
Ananworanich, J
Apateerapong, W
Sankote, J
Hill, A
Hirschel, B
Cooper, D
Lange, J
Phanuphak, P
Ruxrungtham, K
Burger, D
机构
[1] Thai Red Cross AIDS Res Ctr, HIV Netherlands Australia Thailand Res Collaborat, Bangkok, Thailand
[2] Chulalongkorn Univ, Dept Med, Fac Med, Bangkok 10330, Thailand
[3] Int Antiviral Therapy Evaluat Ctr, Amsterdam, Netherlands
[4] Univ Amsterdam, Acad Med Ctr, NL-1012 WX Amsterdam, Netherlands
[5] Roche, Welwyn Garden City, Herts, England
[6] Univ Hosp Geneva, Geneva, Switzerland
[7] Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia
[8] Univ Med Ctr, Nijmegen, Netherlands
关键词
protease inhibitors; HIV; Thailand; pharmacokinetics;
D O I
10.1093/jac/dkh415
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: A pharmacokinetic comparison of three dosing regimens of saquinavir/ritonavir was carried out: 1600/100 mg once-daily with 1000/100 mg twice-daily, and 1600/100 mg once-daily with 2000/100 mg once-daily. Methods: Twenty patients on saquinavir hard gel caps/ritonavir 1600/100 mg once-daily in combination with two nucleoside reverse transcriptase inhibitors for at least 4 weeks were enrolled and randomized to either saquinavir hard gel caps/ritonavir 1000/100 mg twice-daily or 2000/100 mg once-daily. Two pharmacokinetic curves were plotted, at baseline (day 0) and 7 days after the switch. Plasma concentrations were measured at 0, 2, 4, 6, 8, 10, 12 (and 24 for once-daily dosing) hours after drug intake by validated high-performance liquid chromatographic assay (HPLC). The area under the plasma concentration-time curve (AUC(0-24) or AUC(0-12)), maximum and minimum concentration (C-max and C-min) and elimination half-life were calculated using a non-compartmental model. Results: Compared with saquinavir/ritonavir 1600/100 mg once-daily dosing, the saquinavir AUC and C-min improved significantly when dosed as 1000/100 mg twice-daily (53% and 299%, respectively), and as 2000/100 mg once-daily (71% and 65%, respectively). Low C-min in three subjects at baseline was corrected after switch to the other dosages. Saquinavir/ritonavir 2000/100 mg once-daily was also associated with a significant increase in saquinavir C-max (52%) compared with saquinavir/ritonavir 1600/100 mg once-daily. Conclusions: Saquinavir/ritonavir when dosed as 2000/100 mg once-daily or 1000/100 mg twice-daily achieves higher saquinavir plasma levels compared with saquinavir/ritonavir 1600/100 mg once-daily. Taking the convenience of once-daily dosing into consideration, dosage of 2000/100 mg once-daily may be preferred.
引用
收藏
页码:785 / 790
页数:6
相关论文
共 21 条
[1]   Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial [J].
Ananworanich, J ;
Nuesch, R ;
Le Braz, M ;
Chetchotisakd, P ;
Vibhagool, A ;
Wicharuk, S ;
Ruxrungtham, K ;
Furrer, H ;
Cooper, D ;
Hirschel, B .
AIDS, 2003, 17 (15) :F33-F37
[2]  
ANANWORANICH J, 2003, 10 C RETR OPP INF BO
[3]  
BOFFITO M, 2003, 43 INT C ANT AG CHEM
[4]   Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and Saquinavir soft-gelatin capsules boosted with Ritonavir in HIV-1-infected subjects [J].
Cardiello, PG ;
Monhaphol, T ;
Mahanontharit, A ;
van Heeswijk, RP ;
Burger, D ;
Hill, A ;
Ruxrungtham, K ;
Lange, JM ;
Cooper, DA ;
Phanuphak, P .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 32 (04) :375-379
[5]  
Cardiello PG, 2002, J ACQ IMMUN DEF SYND, V29, P464, DOI 10.1097/00042560-200204150-00006
[6]  
CARDIELLO PG, 2002, 9 C RETR OPP INF SEA
[7]   Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: The MaxCmin1 trial [J].
Dragsted, UB ;
Gerstoft, J ;
Pedersen, C ;
Peters, B ;
Duran, A ;
Obel, N ;
Castagna, A ;
Cahn, P ;
Clumeck, N ;
Bruun, JN ;
Benetucci, J ;
Hill, A ;
Cassetti, I ;
Vernazza, P ;
Youle, M ;
Fox, Z ;
Lundgren, JD .
JOURNAL OF INFECTIOUS DISEASES, 2003, 188 (05) :635-642
[8]   Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography [J].
Droste, JAH ;
Verweij-van Wissen, CPWGM ;
Burger, DM .
THERAPEUTIC DRUG MONITORING, 2003, 25 (03) :393-399
[9]   Evaluation of antiretroviral drug measurements by an interlaboratory quality control program [J].
Droste, JAH ;
Aarnoutse, RE ;
Koopmans, PP ;
Hekster, YA ;
Burger, DM .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 32 (03) :287-291
[10]   Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group study 359 [J].
Fletcher, CV ;
Jiang, HY ;
Brundage, RC ;
Acosta, EP ;
Haubrich, R ;
Katzenstein, D ;
Gulick, RM .
JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (07) :1176-1184